Seth Klarman · Q2 2017
Baupost Group
Portfolio at the end of Q2 2017, from the 13F filed August 11, 2017. See the filing on EDGAR ↗
| Company | Weight | Held since | Change |
|---|---|---|---|
| Cheniere Energy LNG · history | 11.5% | Q1 2014 | Reduce 5% |
| Synchrony SYF · history | 10.0% | Q3 2016 | Add 66% |
| Viasat VSAT · history | 10.0% | Q2 2013 or earlier | No change |
| Colony NorthStar CLNS · history | 7.7% | Q1 2017 | No change |
| Allergan AGN · history | 6.8% | Q1 2016 | No change |
| Qorvo QRVO · history | 6.5% | Q1 2017 | Add 25% |
| Twenty-First Century Fox FOXA · history | 6.2% | Q3 2015 | No change |
| Antero Resources AR · history | 5.2% | Q3 2014 | Add 46% |
| Theravance Biopharma TBPH · history | 4.2% | Q2 2014 | No change |
| PBF Energy PBF · history | 4.0% | Q3 2013 | No change |
| Dell Technologies DELL · history | 3.9% | Q3 2016 | No change |
| Qualcomm QCOM · history | 3.3% | Q1 2017 | No change |
| Twenty-First Century Fox FOX · history | 2.3% | Q3 2015 | No change |
| Keryx Biopharmaceuticals KERX · history | 2.1% | Q1 2014 | No change |
| Express Scripts ESRX · history | 1.9% | Q1 2017 | Add 108% |
| Cardinal Health CAH · history | 1.8% | Q4 2016 | Add 97% |
| Veritiv VRTV · history | 1.6% | Q3 2014 | No change |
| Forward Pharma FWP · history | 1.5% | Q4 2014 | Add 14% |
| Avis Budget Group CAR · history | 1.2% | Q2 2017 | Buy |
| Atara Biotherapeutics ATRA · history | 0.9% | Q4 2014 | No change |
| Silver Run Acquisition II SRUN · history | 0.8% | Q2 2017 | Buy |
| ChipMOS IMOS · history | 0.8% | Q2 2013 or earlier | No change |
| Spirit Realty Capital SRC · history | 0.8% | Q2 2017 | Buy |
| Paratek Pharmaceuticals PRTK · history | 0.7% | Q4 2014 | Add 17% |
| GTY Technology GTYH.U · units · history | 0.5% | Q4 2016 | No change |
| Conyers Park Acquisition CPAA · history | 0.5% | Q3 2016 | No change |
| Novagold Resources NG · history | 0.5% | Q2 2013 or earlier | No change |
| Theravance Biopharma TBPH.CV · convertible notes · history | 0.5% | Q4 2016 | No change |
| Permian Resources CDEV · history | 0.4% | Q4 2016 | No change |
| Cascadian Therapeutics CASC · history | 0.4% | Q2 2016 | No change |
| Atlanta Braves Holdings BATRK · history | 0.4% | Q2 2016 | Reduce 35% |
| Credit Acceptance CACC · history | 0.3% | Q2 2016 | Reduce 60% |
| Saban Capital Acquisition SCAC · history | 0.3% | Q4 2016 | No change |
| Sunrun RUN · history | 0.2% | Q3 2015 | No change |
| Innoviva INVA.CV · convertible notes · history | 0.2% | Q3 2014 | Reduce 24% |
| American International Group AIG.WS · warrants · history | 0.1% | Q2 2013 or earlier | Reduce 72% |
| Trilogy Metals TMQ · history | 0.1% | Q2 2013 or earlier | No change |
| Orexigen Therapeutics OREX · history | 0.1% | Q3 2015 | No change |
| Conyers Park Acquisition CPAA.WS · warrants · history | 0.0% | Q3 2016 | No change |
| Saban Capital Acquisition SCAC.WS · warrants · history | 0.0% | Q4 2016 | No change |
| 40 positions | 100.0% |
Weight is the position's share of the total value in this 13F, not of the whole fund. Price is the value divided by the number of shares, so it's the price at the end of the quarter, as the firm reported it. Change compares share counts with Q1 2017, adjusted for stock splits.
Sector weighting
| Energy | 21.2% | |
|---|---|---|
| Health care | 20.9% | |
| Financials & real estate | 20.5% | |
| Media & telecom | 18.8% | |
| Technology | 15.1% | |
| Industrials | 1.8% | |
| Other | 1.2% | |
| Materials | 0.6% |
What changed from Q1 2017
- Buy Avis Budget Group CAR 1.2% of the 13F
- Buy Silver Run Acquisition II SRUN 0.8% of the 13F
- Buy Spirit Realty Capital SRC 0.8% of the 13F
- Add 66% Synchrony SYF 7.1% → 10.0%
- Add 25% Qorvo QRVO 5.8% → 6.5%
- Add 46% Antero Resources AR 3.9% → 5.2%
- Add 108% Express Scripts ESRX 1.0% → 1.9%
- Add 97% Cardinal Health CAH 1.0% → 1.8%
- Add 14% Forward Pharma FWP 1.4% → 1.5%
- Add 17% Paratek Pharmaceuticals PRTK 0.5% → 0.7%
- Reduce 5% Cheniere Energy LNG 12.1% → 11.5%
- Reduce 35% Atlanta Braves Holdings BATRK 0.6% → 0.4%
- Reduce 60% Credit Acceptance CACC 0.6% → 0.3%
- Reduce 24% Innoviva INVA.CV 0.3% → 0.2%
- Reduce 72% American International Group AIG.WS 0.3% → 0.1%
- Sell Innoviva INVA was 1.9%
- Sell McKesson MCK was 1.7%
- Sell Silver Run Acquisition II SRUN.U was 0.8%
- Sell Liberty Ventures LVNTA was 0.8%
- Sell Syngenta SYT was 0.6%
- Sell Cencora COR was 0.5%